Finance Lead - R&D AI Business Initiatives

The Position The Opportunity Doubling down on investment in R&D (Research & Development) doesn't automatically lead to increased outcomes and patient benefits. In fact, the last two decades the Pharma Industry has seen higher R&D costs, a reduced rate of approvals, and fewer commercial opportunities for new drugs. Moreover, in an environment characterized by disruption, we need a high level of financial flexibility to pivot quickly as new opportunities emerge. In other words, we cannot do more …